Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00581035
NCT00581035
Completed
Phase 4

A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants

Wyeth is now a wholly owned subsidiary of Pfizer0 sites712 target enrollmentJanuary 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Healthy
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
712
Primary Endpoint
The pneumococcal and meningococcal responses achieved after the infant series
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
May 2007
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • •Healthy infants aged 6 to 9 weeks

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The pneumococcal and meningococcal responses achieved after the infant series

Time Frame: 7 months

Secondary Outcomes

  • The pneumococcal and meningococcal responses achieved after the toddler dose(13 months)

Similar Trials

Completed
Phase 3
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)Neisseria MeningitidisBacterial InfectionsVirus Diseases
NCT01553279MCM Vaccines B.V.284
Withdrawn
Phase 4
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)Mucopolysaccharidosis (MPS)Hunter Syndrome
NCT05494593Takeda5
Completed
Phase 4
Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior TherapyHepatitis C
NCT00266318Beth Israel Medical Center40
Completed
Phase 4
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.13-valent Pneumococcal VaccinePremature BirthImmunizationSafety
NCT01193335Pfizer200
Completed
Phase 1
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B VaccineVaccine-Preventable DiseasesHepatitis B
NCT06147895CHA Vaccine Institute Co., Ltd.30